Biolargo Inc BLGO

Chemicals Specialty Chemicals

BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company operates through six segments: ONM Environmental, Clyra Medical Technologies (Clyra Medical), BioLargo Engineering (BLEST), BioLargo Canada, Inc. (Canada), BioLargo Energy Technologies, Inc. (BETI), and BioLargo Equipment Solutions & Technologies, Inc. (BEST). ONM Environmental segment engaged in selling odor and volatile organic control products and services. Clyra Medical segment develops and sells medical products based on its technologies. BLEST segment provides professional engineering services on a time and materials basis for outside clients and supports its internal operations as needed. Its Canada segment is the main hub of its scientists researching and developing its technologies. Its BETI segment is engaged in developing its proprietary battery technology. BEST segment manages the sales and distribution of its water treatment products and related services.

OTCQX:BLGO - Post by User

Biolargo Inc

<< Previous

Bullboard Posts

Post by AveragePennyon Nov 15, 2024 10:18am

26 Views

Post# 36314777

BioLargo's Year-to-Date Revenues Up 80%

Annual revenue record secured, with one quarter remaining

WESTMINSTER, CA / ACCESSWIRE / November 15, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced results of its third quarter of 2024:

Revenues ($14.1 million) through September 30, 2024, were 80% greater than the same period in 2023.
Revenue in the third quarter of 2024 increased 63% ($4.4 million) as compared to the third quarter of 2023.
Net loss was $1.1 million for the third quarter, and $2.6 million through September 30, 2024, compared to $1.5 million and $3.6 million for the same periods in 2023.
The company had current assets of $7,394,000 at September 30, 2024, of which $3,882,000 was cash and cash equivalents.
Total stockholder's equity was $6.0 million as of September 30, 2024.

https://www.accesswire.com/943117/biolargos-year-to-date-revenues-up-80